切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (03) : 318 -321. doi: 10.3877/cma.j.issn.2095-3232.2021.03.018

所属专题: 文献

临床研究

血清铁蛋白与原发性肝癌预后的相关性分析
赵静媛1, 李文2, 陈展洪1, 吴祥元1,()   
  1. 1. 510630 广州,中山大学附属第三医院肿瘤内科
    2. 330006 南昌大学第二附属医院肝胆胰外科
  • 收稿日期:2021-03-16 出版日期:2021-06-10
  • 通信作者: 吴祥元
  • 基金资助:
    江西省青年科学基金项目(20181BAB215007)

Correlation between serum ferritin and clinical prognosis of patients with primary liver cancer

Jingyuan Zhao1, Wen Li2, Zhanhong Chen1, Xiangyuan Wu1,()   

  1. 1. Department of Oncology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
  • Received:2021-03-16 Published:2021-06-10
  • Corresponding author: Xiangyuan Wu
引用本文:

赵静媛, 李文, 陈展洪, 吴祥元. 血清铁蛋白与原发性肝癌预后的相关性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 318-321.

Jingyuan Zhao, Wen Li, Zhanhong Chen, Xiangyuan Wu. Correlation between serum ferritin and clinical prognosis of patients with primary liver cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(03): 318-321.

目的

探讨血清铁蛋白(SF)与原发性肝癌(肝癌)预后的关系。

方法

回顾性分析2011年1月至2013年1月在中山大学附属第三医院收治的380例肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男339例女41例;年龄21~86岁,中位年龄54岁。根据参考值范围将患者分为SF正常组及SF升高组。随访患者的生存情况。生存分析采用Kaplan-Meier法和Log-rank检验。SF水平与肝癌患者预后的相关性分析采用Cox比例风险回归模型。

结果

患者1、2、3年生存率分别为62.9%、45.3%、16.8%。多因素Cox回归分析显示,SF、TNM分期、治疗方法为肝癌患者预后的独立危险因素(OR=1.771,3.695,0.224;P<0.05)。生存分析显示,SF升高组患者总体生存明显差于SF正常组(χ2=11.530,P<0.05)。亚组分析显示,TACE治疗患者中SF升高患者总体生存亦明显差于SF正常患者(χ2=10.120,P<0.05)。

结论

SF的表达水平与肝癌预后相关,SF升高预示着患者更短的生存时间。

Objective

To investigate the correlation between the serum ferritin (SF) and clinical prognosis of patients with primary liver cancer (PLC).

Methods

Clinical data of 380 patients with PLC admitted to the Third Affiliated Hospital of Sun Yat-sen University from January 2011 to January 2013 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 339 patients were male and 41 female, aged from 21 to 86 years with a median age of 54 years. According to the SF reference value, all patients were divided into the normal SF and high SF groups. The survival of patients was followed up. Survival analysis was performed by Kaplan-Meier method and Log-rank test. The correlation between SF level and clinical prognosis of PLC patients was analyzed by Cox's proportional hazard regression model.

Results

The 1-, 2- and 3-year survival rates were 62.9%, 45.3%, and 16.8%, respectively. Cox's regression analysis showed that SF, TNM staging and treatment were the independent risk factors for the clinical prognosis of PLC patients (OR=1.771, 3.695, 0.224; P<0.05). Survival analysis showed that the overall survival of PLC patients with elevated SF was significantly worse than those with normal SF (χ2=11.530, P<0.05). For the patients receiving TACE, subgroup analysis result revealed that the overall survival of patients with elevated SF was significantly worse than those with normal SF (χ2=10.120, P<0.05).

Conclusions

The expression level of SF is associated with the clinical prognosis of PLC patients. Elevated SF levels indicates shorter survival time.

表1 影响肝癌患者预后的单因素分析
表2 影响肝癌患者预后的多因素Cox回归分析
图1 380例不同水平SF肝癌患者Kaplan-Meier生存曲线
图2 肝癌TACE治疗患者不同水平SF亚组的Kaplan-Meier生存曲线
[1]
Bhangui P, Saigal S, Gautam D, et al. Incorporating tumour biology to predict HCC recurrence in patients undergoing LDLT using expanded selection criteria[J]. Liver Transpl, 2021, 27(2):209-221.
[2]
Guarino M, Caporaso N, Morisco F. Liver resection is alwaysa good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy[J]. Ann Transl Med, 2020, 8(20):1282.
[3]
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020(371): m3544.
[4]
Cullis JO, Fitzsimons EJ, Griffiths WJ, et al. Investigation and management of a raised serum ferritin[J]. Br J Haematol, 2018, 181(3):331-340.
[5]
程玉萍. 血清铁蛋白检测在临床应用的研究进展[J]. 山西医药杂志(下半月刊), 2013, 42(6):639-640.
[6]
王一帆,金健,李蔼建, 等. 治疗前血清铁蛋白浓度与肺癌患者预后相关性的Meta分析[J]. 中国循证医学杂志, 2020, 20(8): 945-949.
[7]
郭毅,郭伟. 肺癌患者血清铁及铁蛋白水平的变化及其与炎症的相关性[J]. 中国实用医刊, 2019(23):30-32.
[8]
Chen Z, Zhu B, Ou C, et al. Serum ferritin and primary lung cancer[J]. Oncotarget, 2017, 8(54):92643-92651.
[9]
庞顺义,苏学勇,刘永昌, 等. 铁代谢障碍与前列腺癌发生发展的关联研究[J]. 国际泌尿系统杂志, 2018, 38(6):904-907.
[10]
阴志琦,张靖宇. 血清铁蛋白联合前列腺特异性抗原检测对前列腺癌的诊断价值[J]. 癌症进展, 2020, 18(6):593-596.
[11]
高志慧,刘厚宝. 铁代谢与实体肿瘤关系的研究进展[J]. 肿瘤研究与临床, 2019(9):637-640.
[12]
崔中锋. 铁蛋白、甲胎蛋白表达情况对肝癌的诊断价值分析[J]. 西南军医, 2019, 21(4):350-353.
[13]
牛广林,程昌盛,潘卫珍, 等. 血清铁蛋白与肝脏疾病关系的研究进展[J]. 吉林医学, 2018, 39(9):1765-1767.
[14]
Uchino K, Tateishi R, Nakagomi R, et al. Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation[J]. PloS One, 2018, 13(7): e0200943.
[15]
Wu SJ, Zhang ZZ, Cheng NS, et al. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy[J]. Surg Oncol, 2019(29):159-167.
[16]
Pan W, Li W, Zhao J, et al. lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway[J]. Mol Oncol, 2019, 13(10):2246-2258.
[17]
Tingting H, Di S, Xiaoping C, et al. High preoperative serum ferritin predicted poor prognosis in non-metastatic colorectal cancer[J]. Saudi Med J, 2017, 38(3):268-275.
[18]
Gao Y, Wang J, Zhou Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer[J]. Sci Rep, 2018, 8(1): 2732.
[19]
Zhao J, Guo N, Zhang L, et al. Serum CA125 in combination with ferritin improves diagnostic accuracy for epithelial ovarian cancer[J]. Br J Biomed Sci, 2018, 75(2):66-70.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[8] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[9] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[12] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要